Abstract
Background. As the global population ages, metabolic disorders are becoming increasingly prevalent, leading to a significant rise in fatty liver disease among the elderly. Metabolic-associated fatty liver disease, formerly known as non-alcoholic fatty liver disease, is now the most common liver disease. Closely linked to metabolic disorders like obesity, type 2 diabetes, and dyslipidemia, Metabolic-associated fatty liver disease currently affects 24% of the adult population, equating to one billion individuals worldwide. Purpose of study. To analyze the incidence structure of metabolically associated fatty liver disease in the elderly population and to determine the mechanisms of liver aging that affect the prevalence and mortality from this disease in an elderly cohort of individuals. Material and methods of study. For this literature review, we analyzed 32 scientific publications, including reviews, original articles, and meta-analyses, published between 2012 and 2024. We conducted a literature search using databases such as Google Scholar, Web of Science, PubMed, Scopus, and Abridged Index Medicus. Results. Reviewing the available literature sources has revealed the prevalence of fatty liver disease peaking at the age of 40– 50 in men and 60–69 in women but decreasing in the older cohorts (>75 years). The mechanisms of liver cell aging influence the course of this disease in old patients have been identified as well. However, there are no data indicated concerning the direct impact on prevalence and association with fibrosis in the elderly population. Conclusion. Conflicting data on the prevalence of metabolic-associated fatty liver disease among the diagnosed elderly patients highlight the need for further research to realise the mechanisms underlying the age-related changes in the liver. The study of this disease in elderly persons is rather important to improve the quality of life and optimising medical care and developing prevention and treatment strategies.